An Investigator-initiated Linked Study to OCEANIC-AF

Impaired endogenous fibrinolysis is a recently recognised risk factor for thrombotic events in patients with cardiovascular disease. Enhancing endogenous fibrinolysis in such individuals represents a way of reducing thrombosis risk. However, the optimal pharmacotherapy to enhance fibrinolysis is unclear. The aim of this study is to assess the effect of asundexian on endogenous fibrinolysis and compare this to apixaban. If asundexian can enhance endogenous fibrinolysis, this could be used as targeted treatment for patients who despite optimal antithrombotic therapy, demonstrate impaired endogenous fibrinolysis.

NCT Number	NCT06124612
Lead Sponsor	East and North Hertfordshire NHS Trust Collaborators: Liverpool Heart and Chest Hospital NHS Foundation Trust
Conditions	Atrial Fibrillation
Enrollment	100 participants
Start Date	2023-11-03
Primary Completion	2026-09-17 (estimated)
Study Completion	2026-09-17 (estimated)
Updated on ClinicalTrials.gov	2023-11-09